Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

समान संसाधन

• Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
  द्वारा: Moore, Angela Y, और अन्य
  प्रकाशित: (2010)
• Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study
  द्वारा: Valenzuela, F., और अन्य
  प्रकाशित: (2016)
• The experience of pain and redness in patients with moderate to severe plaque psoriasis
  द्वारा: Martin, Mona L., और अन्य
  प्रकाशित: (2015)
• The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
  द्वारा: Reich, K., और अन्य
  प्रकाशित: (2016)
• Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial
  द्वारा: Elewski, B.E., और अन्य
  प्रकाशित: (2019)